282 related articles for article (PubMed ID: 31203994)
21. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
Villa KF; Ryan RJ; Chiarella M; Louie AC
J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
[No Abstract] [Full Text] [Related]
22. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
23. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Lemoli RM; Montesinos P; Jain A
Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
[TBL] [Abstract][Full Text] [Related]
24. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
[TBL] [Abstract][Full Text] [Related]
25. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
[TBL] [Abstract][Full Text] [Related]
27. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
28. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
Cheung E; Perissinotti AJ; Bixby DL; Burke PW; Pettit KM; Benitez LL; Brown J; Scappaticci GB; Marini BL
Ann Hematol; 2019 Mar; 98(3):541-559. PubMed ID: 30666431
[TBL] [Abstract][Full Text] [Related]
29. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
[TBL] [Abstract][Full Text] [Related]
30. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
31. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
[TBL] [Abstract][Full Text] [Related]
32. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Murphy T; Yee KWL
Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
[TBL] [Abstract][Full Text] [Related]
33. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
[TBL] [Abstract][Full Text] [Related]
35. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.
Molica M; Perrone S; Mazzone C; Cesini L; Canichella M; de Fabritiis P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740508
[TBL] [Abstract][Full Text] [Related]
36. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
[TBL] [Abstract][Full Text] [Related]
37. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
van der Holt B; Löwenberg B; Burnett AK; Knauf WU; Shepherd J; Piccaluga PP; Ossenkoppele GJ; Verhoef GE; Ferrant A; Crump M; Selleslag D; Theobald M; Fey MF; Vellenga E; Dugan M; Sonneveld P
Blood; 2005 Oct; 106(8):2646-54. PubMed ID: 15994288
[TBL] [Abstract][Full Text] [Related]
38. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Lee D; Jain AG; Deutsch Y; Eatrides J; Chan O; Padron E; Kuykendall A; Komrokji R; Lancet J; Sallman D; Talati C; Sweet K
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):774-779. PubMed ID: 35760672
[TBL] [Abstract][Full Text] [Related]
39. Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes.
Jensen IS; Wu E; Sacks NC; Cyr PL; Chung KC
Am Health Drug Benefits; 2018 Oct; 11(7):380-386. PubMed ID: 30647825
[TBL] [Abstract][Full Text] [Related]
40. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
